Fingolimod failure in progressive MS INFORMS future trials

被引：0
|
作者：
Andrew L. Smith
Jeffrey A. Cohen
机构：
[1] Mellen Center for Multiple Sclerosis Treatment and Research in the Neurological Institute,
[2] Cleveland Clinic,undefined
来源：
Nature Reviews Neurology | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Fingolimod is approved for the treatment of relapsing–remitting multiple sclerosis (MS), and evidence suggests that it has neuroprotective effects. The recent INFORMS phase III trial in primary progressive MS demonstrated no beneficial effects of fingolimod on disability progression or whole-brain atrophy, but provides important information for future therapeutic development.
引用
收藏
页码：253 / 254
页数：1
相关论文
共 50 条
  • [31] Clinical trials in MS - achievements, current and future challenges
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S14 - S14
  • [32] The nine hole peg test as an outcome measure in progressive MS trials
    Koch, Marcus W.
    Repovic, Pavle
    Mostert, Jop
    Bowen, James D.
    Comtois, Jacynthe
    Strijbis, Eva
    Uitdehaag, Bernard
    Cutter, Gary
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 69
  • [33] Do we need more clinical trials in secondary progressive MS?
    不详
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 60
  • [34] Comment on extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
    Ines Gaitan, Maria
    Correale, Jorge
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (04) : 617 - 618
  • [35] Progressive multifocal leukoencephalopathy after fingolimod treatment
    Berger, Joseph R.
    Cree, Bruce A.
    Greenberg, Benjamin
    Hemmer, Bernhard
    Ward, Brian J.
    Dong, Victor M.
    Merschhemke, Martin
    NEUROLOGY, 2018, 90 (20) : E1815 - E1821
  • [36] Control of chronic relapsing progressive EAE with fingolimod
    Al-Izki, Gareth Pryce Sarah
    Baker, David
    Giouannoni, Gavin
    NEUROLOGY, 2008, 70 (11) : A29 - A29
  • [37] More flexibility for future MS trials: adaptive designs.
    Chataway, J.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 30 - 30
  • [38] When the past informs our future
    Labella, Abigail
    ELIFE, 2021, 10
  • [39] Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - NO
    Fox, Robert J.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (04) : 506 - 508
  • [40] Learning from recent trials and shaping the future of acute heart failure trials
    Mentz, Robert J.
    Felker, Gary Michael
    Ahmad, Tariq
    Peacock, William Frank
    Pitt, Bertram
    Fiuzat, Mona
    Maggioni, Aldo P.
    Gheorghiade, Mihai
    Ando, Yuki
    Pocock, Stuart J.
    Zannad, Faiez
    O'Connor, Christopher M.
    AMERICAN HEART JOURNAL, 2013, 166 (04) : 629 - 635
12345